Non-Alcoholic Steatohepatitis (NASH) Market Overview 2026–2030 With Insights On Industry Developments
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Are The Market Size Estimates For The Non-Alcoholic Steatohepatitis (NASH) Market In 2026 And 2030?
The market size for non-alcoholic steatohepatitis (nash) has experienced significant expansion in recent years. Looking ahead, it is projected to expand from $6.06 billion in 2025 to $8.04 billion in 2026, achieving a compound annual growth rate (CAGR) of 32.7%. The historical growth witnessed in this market is primarily linked to factors such as restricted awareness of nash, the scarcity of potent treatment options, a strong reliance on lifestyle changes, the widespread occurrence of metabolic disorders, and a fragmented market structure.
The non-alcoholic steatohepatitis (NASH) market size is anticipated to undergo significant growth over the next few years. It is forecast to expand to $24.32 billion in 2030, achieving a compound annual growth rate (CAGR) of 31.9%. This expansion during the forecast period can be attributed to advancements in targeted therapies, increased healthcare expenditure, the growing adoption of non-invasive diagnostics, the expansion of pharmaceutical pipelines, and rising collaborations for research and development. Key trends observed in the forecast period include the increasing prevalence of obesity and type 2 diabetes, the development of non-invasive diagnostic tools, heightened research in liver fibrosis therapies, an increase in personalized and targeted drug treatments, and the expansion of hospital and retail pharmacy networks.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8805&type=smp
Which Factors Are Influencing The Growth Of The Non-Alcoholic Steatohepatitis (NASH) Market?
The increasing incidence of obesity is fueling the demand within the non-alcoholic steatohepatitis (NASH) market moving forward. Obesity refers to an abnormal or excessive accumulation of fat that presents a health risk, or a body weight exceeding what is considered healthy or standard for an individual’s height. With the increased prevalence of non-alcoholic fatty liver disease, linked to the growing obesity pandemic, NASH is anticipated to emerge as the primary cause of severe liver disease in the coming decades, thus stimulating the demand for NASH treatments and associated medications. For example, data from May 2025, provided by the UK-based Government Digital Service, indicated that during 2023 to 2024, the prevalence of overweight individuals (including those with obesity) among adults was greater for men (69.7%) compared to women (59.2%). Conversely, the prevalence of obesity specifically in adults was higher among women (26.9%) than men (26.2%). Consequently, the escalating number of obesity cases is expected to propel the expansion of the non-alcoholic steatohepatitis (NASH) market.
How Are Segments Identified Within The Non-Alcoholic Steatohepatitis (NASH) Market Segment Framework?
The non-alcoholic steatohepatitis (nash) market covered in this report is segmented –
1) By Dosage Form: Solid, Liquid
2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products
3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider
5) By Application: Oral, Parenteral
Subsegments:
1) By Solid: Tablets, Capsules, Other Solid Dosage Forms
2) By Liquid: Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms
Which Trends Are Influencing Demand In The Non-Alcoholic Steatohepatitis (NASH) Market?
Leading corporations active in the non-alcoholic steatohepatitis (NASH) market are developing thyroid hormone receptor-beta (THR-beta) agonists to improve liver metabolism, lessen liver fat accumulation, and enhance liver function. These THR-beta agonists are compounds specifically designed to activate the thyroid hormone receptor-beta subtype, a vital receptor controlling metabolism, growth, and development. For example, in March 2024, the Food and Drug Administration, a US regulatory agency, granted approval for Rezdiffra (resmetirom), a thyroid hormone receptor-beta agonist, making it the first treatment for adults with noncirrhotic NASH exhibiting moderate to advanced liver scarring (fibrosis). Through its selective activation of the THR-beta receptor, Rezdiffra aids in regulating lipid metabolism, consequently reducing intrahepatic triglycerides and overall liver fat.
Who Are The Companies Competing Within The Non-Alcoholic Steatohepatitis (NASH) Market?
Major companies operating in the non-alcoholic steatohepatitis (nash) market are NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens
Get The Full Non-Alcoholic Steatohepatitis (NASH) Market Report:
Which Geographic Region Dominates The Non-Alcoholic Steatohepatitis (NASH) Market?
North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2025. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Non-Alcoholic Steatohepatitis (NASH) Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Non-Alcoholic Steatohepatitis (NASH) Market 2026, By The Business Research Company
Non Alcoholic Steatohepatitis Treatment Market Report 2026
Non Alcoholic Steatohepatitis Treatment Market Report 2026
Non Alcoholic Steatohepatitis Biomarkers Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
